COVID-19: EMA Makes Scientific Advice Free & Fast For Drug, Vaccine Developers
The European Medicines Agency has waived its fee for scientific advice for developers of potential vaccines and treatments for the coronavirus
You may also be interested in...
New Powers For EMA Under EU ‘Future Proofing’ Plans
A new legislative proposal is seeking to empower the European Medicines Agency in tracking potential shortages of drugs and medical devices and enable the agency to play a greater role in coordinating clinical trials and vaccine research during health emergencies.
EMA Clarifies Fast-Track Mechanisms For COVID-19 Medicines & Vaccines
From speeding up PIP agreements to starting rolling reviews, the European Medicines Agency has explained how it is accelerating its regulatory procedures for COVID-19 treatments and vaccines.
Upstaza: First Gene Therapy For Ultra-Rare Disorder AADC Deficiency Receives English Funding
The single-dose gene therapy for aromatic L-amino acid decarboxylase in children is to be made available on the National Health Service following a confidential commercial deal between NHS England and PTC Therapeutics.